<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00535002</url>
  </required_header>
  <id_info>
    <org_study_id>P50DA016511-1</org_study_id>
    <secondary_id>P50DA016511</secondary_id>
    <nct_id>NCT00535002</nct_id>
  </id_info>
  <brief_title>The Effect of Yohimbine on Cocaine Cue Reactivity</brief_title>
  <official_title>SCOR on Sex and Gender Factors Affecting Women's Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Research on Women's Health (ORWH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stress and cues reminiscent of cocaine use promote craving and relapse in cocaine dependent
      individuals. In addition, there appears to be gender differences in determinants of relapse
      to drug use following abstinence in cocaine-dependent individuals. Therefore the purpose of
      the present study is to study the role of hormonal status on the response to cocaine-related
      cues with or without stress in cocaine-dependent women and men.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cocaine dependence is an insidious disease underscored by a strong propensity to relapse
      despite knowledge of the repercussions of continued drug-use. Stress and cocaine cues produce
      craving and ultimately relapse in cocaine dependent individuals. Pre-clinical research has
      demonstrated sex differences in response to cocaine-conditioned cues and cocaine-primed
      reinstatement, which correlates well with reduced plasma progesterone levels. Interestingly,
      this is consistent with a growing body of clinical literature indicating that progesterone
      may decrease the reinforcing properties of stimulants in women. Gender differences in the
      response to a social stressor and cocaine cues in cocaine-dependent individuals have been
      demonstrated in human laboratory studies, however, the interaction of stress and cues and the
      effect of hormonal status on response have not been explored. This study examines the role of
      hormonal status on the response to cocaine-related cues with or without a pharmacological
      stressor (yohimbine) in cocaine-dependent women and men. As a further integration of the
      research focus this study also explores the relationship between impulsivity and craving.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cocaine Craving</measure>
    <time_frame>Post cocaine cue exposure</time_frame>
    <description>Cocaine-dependent participants were pre-treated with either yohimbine or placebo provided subjective ratings of cocaine craving immediately following cocaine cue exposure.
The scale used was the Within Sessions Ratings Scales (Childress AR, McLellan AT, O'Brien CP (1986) Conditioned responses in a methadone population. A comparison of laboratory, clinic, and natural settings. Journal of Substance Abuse Treatment 3:173-179.) Craving was rated on a scale of 0-10 with 0 being Not At All and 10 being Extremely.</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Cocaine Related Disorders</condition>
  <arm_group>
    <arm_group_label>Cocaine Females, Yohimbine then Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cocaine dependent females, received yohimbine day 1 and placebo day 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cocaine Females, Placebo the Yohimbine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cocaine dependent females, received placebo day 1 and yohimbine day 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cocaine Males, Yohimbine then Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cocaine dependent males, received yohimbine day 1 and placebo day 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cocaine Males, Placebo thenYohimbine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cocaine dependent males, received placebo day 1 and yohimbine day 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Females, Yohimbine then Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Non-dependent females, received yohimbine day 1 and placebo day 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Females, Placebo then Yohimbine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Non-dependent females, received placebo day 1 and yohimbine day 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Males, Yohimbine then Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Non-dependent males, received yohimbine day 1 and placebo day 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Males, Placebo then Yohimbine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Non-dependent males, received placebo day 1 and yohimbine day 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Yohimbine</intervention_name>
    <description>Participants were pre-treated with either yohimbine or placebo.</description>
    <arm_group_label>Cocaine Females, Yohimbine then Placebo</arm_group_label>
    <arm_group_label>Cocaine Females, Placebo the Yohimbine</arm_group_label>
    <arm_group_label>Cocaine Males, Yohimbine then Placebo</arm_group_label>
    <arm_group_label>Cocaine Males, Placebo thenYohimbine</arm_group_label>
    <arm_group_label>Control Females, Yohimbine then Placebo</arm_group_label>
    <arm_group_label>Control Females, Placebo then Yohimbine</arm_group_label>
    <arm_group_label>Control Males, Yohimbine then Placebo</arm_group_label>
    <arm_group_label>Control Males, Placebo then Yohimbine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Cocaine Females, Yohimbine then Placebo</arm_group_label>
    <arm_group_label>Cocaine Females, Placebo the Yohimbine</arm_group_label>
    <arm_group_label>Cocaine Males, Yohimbine then Placebo</arm_group_label>
    <arm_group_label>Cocaine Males, Placebo thenYohimbine</arm_group_label>
    <arm_group_label>Control Females, Yohimbine then Placebo</arm_group_label>
    <arm_group_label>Control Females, Placebo then Yohimbine</arm_group_label>
    <arm_group_label>Control Males, Yohimbine then Placebo</arm_group_label>
    <arm_group_label>Control Males, Placebo then Yohimbine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be able to provide informed consent and function at an intellectual
             level sufficient to allow accurate completion of all assessment instruments.

          -  Subjects must consent to remain abstinent from all drugs of abuse (except nicotine)
             for a three-day period immediately prior to the CTRC admission. Nicotine dependence
             can affect HPA function (Baron et al., 1995) therefore it would be ideal to exclude
             subjects with nicotine use. Because of the high comorbidity of cocaine and nicotine
             dependence, this would seriously compromise the feasibility of recruitment.
             Individuals with alcohol dependence will be excluded. However because of the high
             comorbidity of alcohol use and cocaine dependence, individuals with alcohol abuse will
             be included. Also, due to the high comorbidity of cocaine and marijuana dependence,
             and limited evidence that marijuana use affects HPA function, subjects with marijuana
             dependence will be included.

          -  Subjects with ADHD will be included. Because ADHD is commonly characterized by
             impulsivity, ADHD severity ratings will be determined and controlled for in data
             analysis.

          -  Subjects must consent to random assignment.

          -  Subjects must consent to outpatient admission to the CTRC and two overnight admissions
             to the Medical University Hospital.

        Exclusion Criteria:

          -  Women who are pregnant, nursing or of childbearing potential and not practicing an
             effective means of birth control.

          -  Women with premenstrual dysphoric disorder as this may impact on the response to the
             stress test procedure (Woods et al., 1994).

          -  Women receiving depot medroxyprogesterone acetate as a form of birth control.

          -  Subjects with evidence of or a history of significant hematological, endocrine,
             cardiovascular, pulmonary, renal, gastrointestinal, or neurological disease including
             diabetes, as these conditions may affect physiological/subjective responses.

          -  Subjects with Addison's disease, Cushing's disease or other diseases of the adrenal
             cortex likely to affect hormonal/neuroendocrine status.

          -  Subjects with a history of or current psychotic disorder or bipolar affective disorder
             as these may interfere with subjective measurements.

          -  Subjects with current major depressive disorder or post-traumatic stress disorder as
             these disorders are associated with characteristic changes in stress response.

          -  Subjects with panic disorder, as yohimbine may precipitate panic attacks.

          -  Subjects receiving synthetic glucocorticoid therapy, any exogenous steroid therapy, or
             treatment with other agents that interfere with hormonal measurements within one month
             of test session.

          -  Subjects taking any psychotropic medications,antidepressants, opiates or opiate
             antagonists because these may affect test response. Subjects taking SSRI's will be
             included.

          -  Subjects with any acute illness or fever. Individuals who otherwise meet study
             criteria will be rescheduled for evaluation for participation.

          -  Subjects who are obese (BMI&gt;35) as this may interfere with hormonal status.

          -  Subjects who are unwilling or unable to maintain abstinence from alcohol and other
             drugs of abuse (except nicotine) for three days prior to the stress task procedure.

          -  Subjects meeting DSM-IV criteria for substance dependence (other than nicotine,
             alcohol, marijuana or cocaine as appropriate) within the past 60 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen T Brady, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina-GCRC</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2007</study_first_submitted>
  <study_first_submitted_qc>September 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2007</study_first_posted>
  <results_first_submitted>July 31, 2013</results_first_submitted>
  <results_first_submitted_qc>May 4, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 7, 2017</results_first_posted>
  <last_update_submitted>May 4, 2017</last_update_submitted>
  <last_update_submitted_qc>May 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cocaine Addiction</keyword>
  <keyword>Cocaine Dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Yohimbine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Cocaine-dependent and control males and females between the ages of 18 and 65 were recruited between July 2008 and July 2012. Participants were primarily recruited through newspaper advertisements, and study procedures were conducted in the Clinical Neuroscience Division and Clinical and Translational Research Center of MUSC.</recruitment_details>
      <pre_assignment_details>A total of 400 people consented to study participation; 171 met study inclusion criteria. 115 people completed study procedures, and the data of 112 subjects was included for analysis. Data from two participants were excluded from analysis because it was discovered later that they did not meet eligibility requirements.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cocaine Females, Yohimbine Then Placebo</title>
          <description>Cocaine-dependent females, Yohimbine then placebo</description>
        </group>
        <group group_id="P2">
          <title>Cocaine Males, Yohimbine Then Placebo</title>
          <description>Cocaine-dependent males, Yohimbine then placebo</description>
        </group>
        <group group_id="P3">
          <title>Control Females, Yohimbine Then Placebo</title>
          <description>Non-dependent females, Yohimbine then placebo</description>
        </group>
        <group group_id="P4">
          <title>Control Males, Yohimbine Then Placebo</title>
          <description>Non-dependent males, Yohimbine then placebo</description>
        </group>
        <group group_id="P5">
          <title>Cocaine Females, Placebo Then Yohimbine</title>
          <description>Cocaine females-dependent females, Placebo then yohimbine</description>
        </group>
        <group group_id="P6">
          <title>Cocaine Males, Placebo Then Yohimbine</title>
          <description>Cocaine-dependent males, Placebo then Yohimbine</description>
        </group>
        <group group_id="P7">
          <title>Control Females, Placebo Then Yohimbine</title>
          <description>Non-dependent females, placebo then yohimbine</description>
        </group>
        <group group_id="P8">
          <title>Control Males, Placebo Then Yohimbine</title>
          <description>Non-dependent males, placebo then yohimbine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="17"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="17"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cocaine Females, Yohimbine Then Placebo</title>
          <description>Cocaine-dependent females, received yohimbine day 1, placebo day 2</description>
        </group>
        <group group_id="B2">
          <title>Cocaine Females, Placebo Then Yohimbine</title>
          <description>Cocaine-dependent females, received placebo day 1, yohimbine day 2</description>
        </group>
        <group group_id="B3">
          <title>Cocaine Males, Yohimbine Then Placebo</title>
          <description>Cocaine-dependent males, received yohimbine day 1, placebo day 2</description>
        </group>
        <group group_id="B4">
          <title>Cocaine Males, Placebo Then Yohimbine</title>
          <description>Cocaine-dependent males, received placebo day 1, yohimbine day 2</description>
        </group>
        <group group_id="B5">
          <title>Control Females, Yohimbine Then Placebo</title>
          <description>non-dependent females, received yohimbine day and placebo day 2</description>
        </group>
        <group group_id="B6">
          <title>Control Females, Placebo Then Yohimbine</title>
          <description>non-dependent females, received placebo day and yohimbine day 2</description>
        </group>
        <group group_id="B7">
          <title>Control Males, Yohimbine Then Placebo</title>
          <description>non-dependent males, received yohimbine day and placebo day 2</description>
        </group>
        <group group_id="B8">
          <title>Control Males, Placebo Then Yohimbine</title>
          <description>non-dependent males, received placebo day and yohimbine day 2</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="17"/>
            <count group_id="B5" value="13"/>
            <count group_id="B6" value="12"/>
            <count group_id="B7" value="14"/>
            <count group_id="B8" value="16"/>
            <count group_id="B9" value="112"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="14"/>
                    <measurement group_id="B8" value="16"/>
                    <measurement group_id="B9" value="112"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.1" spread="10.1"/>
                    <measurement group_id="B2" value="37.8" spread="11.2"/>
                    <measurement group_id="B3" value="39.8" spread="10.9"/>
                    <measurement group_id="B4" value="38.7" spread="10.1"/>
                    <measurement group_id="B5" value="36.2" spread="13.2"/>
                    <measurement group_id="B6" value="32.1" spread="13.2"/>
                    <measurement group_id="B7" value="32.7" spread="13.3"/>
                    <measurement group_id="B8" value="32.3" spread="12.6"/>
                    <measurement group_id="B9" value="36.8" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="14"/>
                    <measurement group_id="B8" value="16"/>
                    <measurement group_id="B9" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="14"/>
                    <measurement group_id="B8" value="16"/>
                    <measurement group_id="B9" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cocaine Craving</title>
        <description>Cocaine-dependent participants were pre-treated with either yohimbine or placebo provided subjective ratings of cocaine craving immediately following cocaine cue exposure.
The scale used was the Within Sessions Ratings Scales (Childress AR, McLellan AT, O'Brien CP (1986) Conditioned responses in a methadone population. A comparison of laboratory, clinic, and natural settings. Journal of Substance Abuse Treatment 3:173-179.) Craving was rated on a scale of 0-10 with 0 being Not At All and 10 being Extremely.</description>
        <time_frame>Post cocaine cue exposure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cocaine Females Yohimbine</title>
            <description>Cocaine-dependent females pre-treated with yohimbine</description>
          </group>
          <group group_id="O2">
            <title>Cocaine Females Placebo</title>
            <description>Cocaine-dependent females pre-treated with placebo</description>
          </group>
          <group group_id="O3">
            <title>Cocaine Males Yohimbine</title>
            <description>Cocaine-dependent males pre-treated with yohimbine</description>
          </group>
          <group group_id="O4">
            <title>Cocaine Males Placebo</title>
            <description>Cocaine-dependent males pre-treated with placebo</description>
          </group>
          <group group_id="O5">
            <title>Control Females Yohimbine</title>
          </group>
          <group group_id="O6">
            <title>Control Females Placebo</title>
          </group>
          <group group_id="O7">
            <title>Control Males Yohimbine</title>
          </group>
          <group group_id="O8">
            <title>Control Males Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Cocaine Craving</title>
          <description>Cocaine-dependent participants were pre-treated with either yohimbine or placebo provided subjective ratings of cocaine craving immediately following cocaine cue exposure.
The scale used was the Within Sessions Ratings Scales (Childress AR, McLellan AT, O'Brien CP (1986) Conditioned responses in a methadone population. A comparison of laboratory, clinic, and natural settings. Journal of Substance Abuse Treatment 3:173-179.) Craving was rated on a scale of 0-10 with 0 being Not At All and 10 being Extremely.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="3.6"/>
                    <measurement group_id="O2" value="3.4" spread="3.6"/>
                    <measurement group_id="O3" value="3.0" spread="2.9"/>
                    <measurement group_id="O4" value="2.7" spread="3.1"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                    <measurement group_id="O7" value="0" spread="0"/>
                    <measurement group_id="O8" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cocaine Females</title>
          <description>Cocaine-dependent females</description>
        </group>
        <group group_id="E2">
          <title>Cocaine Males</title>
          <description>Cocaine-dependent males</description>
        </group>
        <group group_id="E3">
          <title>Control Females</title>
          <description>Non-dependent females</description>
        </group>
        <group group_id="E4">
          <title>Control Males</title>
          <description>Non-dependent males</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. McRae-Clark</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>843-792-5216</phone>
      <email>mcraeal@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

